Godavari drugs Limited has submitted its mandatory compliance certificate under SEBI regulations for the quarter ended March 31, 2026. The pharmaceutical company filed the certificate with BSE Limited on April 8, 2026, fulfilling its regulatory obligations under the Securities and Exchange Board of India framework.

SEBI Compliance Certificate Details

The certificate was issued under Regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018, covering the quarter ended March 31, 2026. CIL Securities Limited, serving as the company's Registrar and Share Transfer Agent, issued the confirmation certificate on April 7, 2026.

Dematerialization Compliance Confirmation

CIL Securities Limited confirmed that all securities received from depository participants for dematerialization during the quarter were properly processed according to regulatory requirements. The registrar verified that securities comprised in the certificates have been listed on stock exchanges where the company's earlier issued securities are traded.

The compliance process included several key activities:

• Securities received from depository participants were confirmed to depositories
• Security certificates received for dematerialization were mutilated and cancelled after due verification
• Names of depositories were substituted in the Register of Members as registered owners
• All processes were completed within the stipulated timeframe

Regulatory Submission Process

Company Secretary and Compliance Officer Venkatesh Achanta digitally signed and submitted the certificate to BSE Limited. The submission was made with reference to the company's scrip code 530317, ensuring proper identification and record-keeping by the stock exchange.

The certificate submission demonstrates Godavari Drugs Limited's adherence to SEBI's depository regulations, which are designed to ensure transparency and proper handling of securities in dematerialized form. This quarterly compliance requirement helps maintain investor confidence and regulatory oversight in the securities market.

Godavari Drugs Limited's Board of Directors convened on March 18, 2026, to approve significant capital raising initiatives through the allotment of convertible warrants and equity shares on preferential basis. The meeting, held at the company's registered office, concluded key decisions that strengthen the pharmaceutical company's capital structure.

Convertible Warrants Allotment

The board approved the allotment of 23,60,065 convertible warrants at a warrant issue price of Rs.89/- each, aggregating to Rs.21,00,45,785/-. These warrants were issued exclusively to promoters on preferential basis, following the in-principle approval granted by BSE Limited.

The company has already received 25% of the warrant issue price, totaling Rs.5,25,11,446.25/-, representing the warrant subscription price. The warrants were distributed among ten promoter entities, with Mukund Kakani receiving the largest allocation of 4,69,000 warrants, followed by Sushma Kakani with 4,23,000 warrants and Mohit Jaju with 4,00,065 warrants.

Equity Shares Allotment

Simultaneously, the board approved the allotment of 25,96,935 equity shares of face value Rs.10/- each at an issue price of Rs.89/- per share. The shares carry a premium of Rs.79/- per share, with the total allotment value reaching Rs.23,11,27,215/-.

The equity shares were allocated to both promoters and non-promoters, with the majority going to public category investors. Notable allocations include Suryatej Advisors LLP and Sachin Kasera, each receiving 2,24,725 shares, while Satya Foundation also received an identical allocation.

Prashant Shrimal's SEBI Disclosure Filing

Promoter group member Prashant Shrimal has filed a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, confirming his acquisition of 1,12,360 equity shares through preferential allotment on March 18, 2026. The disclosure was submitted to BSE Limited on March 23, 2026, through Company Secretary Venkatesh Achanta.

Regulatory Compliance Details

The SEBI disclosure reveals that Shrimal's acquisition was executed through preferential allotment at Rs.89/- per share, with the company's equity share capital increasing from Rs.7,53,05,000/- divided into 75,30,500 shares to Rs.10,12,74,350 divided into 1,01,27,435 equity shares post-allotment. The total diluted share capital stands at Rs.12,48,75,000/- divided into 1,24,87,500 fully paid-up equity shares.

Other Promoter Disclosures

Following the warrant allotment, multiple promoters filed disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Other promoters including Mohit Jaju, Mukund Kakani, Ileshir Jaju, Sushma Kakani, Priyanka Jaju, Kamala Jaju, Tanushree Kakani, Ghanshyam Jaju, and Aksheit Kakani also filed similar disclosures for their respective warrant acquisitions.

Key Promoter Holdings Summary

Capital Structure Impact

Both allotments were executed pursuant to the in-principle approval granted by BSE Limited through Letter Reference No. LOD/PREF/PB/FIP/1795/2025-26 dated March 4, 2026. The preferential allotment process demonstrates the company's adherence to regulatory requirements and transparent capital raising practices.

The successful completion of these allotments positions Godavari Drugs Limited for enhanced financial flexibility and growth opportunities in the pharmaceutical sector. The regulatory disclosures by multiple promoters ensure compliance with SEBI takeover regulations and maintain transparency in substantial acquisition reporting.